Contingency in innovation and the role of national systems: Taxol and taxotère in the USA and France

Vivien Walsh; Muriel Le Roux

doi:10.1016/j.respol.2004.07.009

Contingency in innovation and the role of national systems: Taxol and taxotère in the USA and France

Vivien Walsh, Muriel Le Roux

Alliance Manchester Business School Administration

Research output: Contribution to journal › Article › peer-review

Abstract

A very rich collection of archival material is used to compare two anticancer drugs commercialised by multinationals collaborating with public sector research, one in the USA and one in France. The framework of national innovation systems is used to compare the innovative environments for each development (different institutional structures, research programmes, financing, industry-academic-government relationships, environmental concern, and intellectual property regimes). The empirical work was able to bring out the nuances and subtleties of each environment, the way in which innovation took place in practice, and some striking differences from what stereotypical accounts of innovation in each country would have suggested. © 2004 Elsevier B.V. All rights reserved.

Original language	English
Pages (from-to)	1307-1327
Number of pages	20
Journal	Research Policy
Volume	33
Issue number	9
DOIs	https://doi.org/10.1016/j.respol.2004.07.009
Publication status	Published - Nov 2004

Keywords

France
National innovation system
Pharmaceuticals
Taxol
USA

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.respol.2004.07.009

Cite this

@article{b36d01a1d18b491f9b152882a990472b,

title = "Contingency in innovation and the role of national systems: Taxol and taxot{\`e}re in the USA and France",

abstract = "A very rich collection of archival material is used to compare two anticancer drugs commercialised by multinationals collaborating with public sector research, one in the USA and one in France. The framework of national innovation systems is used to compare the innovative environments for each development (different institutional structures, research programmes, financing, industry-academic-government relationships, environmental concern, and intellectual property regimes). The empirical work was able to bring out the nuances and subtleties of each environment, the way in which innovation took place in practice, and some striking differences from what stereotypical accounts of innovation in each country would have suggested. {\textcopyright} 2004 Elsevier B.V. All rights reserved.",

keywords = "France, National innovation system, Pharmaceuticals, Taxol, USA",

author = "Vivien Walsh and {Le Roux}, Muriel",

year = "2004",

month = nov,

doi = "10.1016/j.respol.2004.07.009",

language = "English",

volume = "33",

pages = "1307--1327",

journal = "Research Policy",

issn = "0048-7333",

publisher = "Elsevier BV",

number = "9",

}

TY - JOUR

T1 - Contingency in innovation and the role of national systems: Taxol and taxotère in the USA and France

AU - Walsh, Vivien

AU - Le Roux, Muriel

PY - 2004/11

Y1 - 2004/11

N2 - A very rich collection of archival material is used to compare two anticancer drugs commercialised by multinationals collaborating with public sector research, one in the USA and one in France. The framework of national innovation systems is used to compare the innovative environments for each development (different institutional structures, research programmes, financing, industry-academic-government relationships, environmental concern, and intellectual property regimes). The empirical work was able to bring out the nuances and subtleties of each environment, the way in which innovation took place in practice, and some striking differences from what stereotypical accounts of innovation in each country would have suggested. © 2004 Elsevier B.V. All rights reserved.

AB - A very rich collection of archival material is used to compare two anticancer drugs commercialised by multinationals collaborating with public sector research, one in the USA and one in France. The framework of national innovation systems is used to compare the innovative environments for each development (different institutional structures, research programmes, financing, industry-academic-government relationships, environmental concern, and intellectual property regimes). The empirical work was able to bring out the nuances and subtleties of each environment, the way in which innovation took place in practice, and some striking differences from what stereotypical accounts of innovation in each country would have suggested. © 2004 Elsevier B.V. All rights reserved.

KW - France

KW - National innovation system

KW - Pharmaceuticals

KW - Taxol

KW - USA

U2 - 10.1016/j.respol.2004.07.009

DO - 10.1016/j.respol.2004.07.009

M3 - Article

SN - 0048-7333

VL - 33

SP - 1307

EP - 1327

JO - Research Policy

JF - Research Policy

IS - 9

ER -

Contingency in innovation and the role of national systems: Taxol and taxotère in the USA and France

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this